MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration on May 12, 2026 Accelerated Advice Approved Multiple Myeloma Neoplasm, Residual oncology trials Solid Neoplasm trial design United States Food and Drug Administration +